High expression of XP genes, like ERCC1, has also been correlated with poor therapy response in different cancer entities like e.g. non-small cell lung cancer, esophageal cancer, breast cancer, colorectal cancer, as well as head and neck cancer [58–61]. Here, ERCC1 is linked to colorectal cancer.